口服小分子螯合剂在孤独症谱系障碍青少年中的安全性与靶点结合:一项开放标签1b/2a期试验
这项开放标签、单队列、多递增剂量1b/2a期试验在新西兰和澳大利亚纳入30名伴有胃肠道症状的孤独症谱系障碍青少年,评估口服胃肠道限制性吸附剂AB-2004的安全性。AB-2004在所有剂量水平均显示良好安全性和耐受性,未发现药物相关严重不良事件,并观察到尿和血浆中特定肠道细菌代谢物水平较基线显著降低,提示靶点结合。
要点
- AB-2004在所有剂量水平安全性和耐受性良好,未发现药物相关严重不良事件。
- 治疗前后尿和血浆中特定肠道细菌代谢物水平显著降低,提示靶点结合。
- 开放标签研究结果提示靶向肠道来源代谢物可能改善孤独症谱系障碍相关症状。
核心结论
- 开放标签研究结果提示,用口服吸附剂靶向肠道来源代谢物是改善孤独症谱系障碍相关症状的安全且耐受性良好的方法,从而支持开展更大规模安慰剂对照试验。
研究设计与样本
- 开放标签、单队列、多递增剂量1b/2a期临床试验,在新西兰和澳大利亚纳入30名伴有胃肠道症状的孤独症谱系障碍青少年。
主要发现
- AB-2004在所有剂量水平均显示良好安全性和耐受性,未发现药物相关严重不良事件。
- 基线至AB-2004治疗结束时,尿和血浆中特定肠道细菌代谢物水平显著降低,提示靶点结合。
- 观察到多个探索性行为终点改善,在事后分析中焦虑和易激惹以及胃肠道健康改善最显著,见于8周治疗后。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autism spectrum disorder (ASD) is defined by hallmark behaviors involving reduced communication and social interaction as well as repetitive activities and restricted interests. ASD represents a broad spectrum, from minimally affected individuals to those requiring intense support, with additional manifestations often including anxiety, irritability/aggression and altered sensory processing. Gastrointestinal (GI) issues are also common in ASD, and studies have identified changes in the gut microbiome of individuals with ASD compared to control populations, complementing recent findings of differences in gut-derived metabolites in feces and circulation. However, a role for the GI tract or microbiome in ASD remains controversial. Here we report that an oral GI-restricted adsorbent (AB-2004) that has affinity for small aromatic or phenolic molecules relieves anxiety-like behaviors that are driven by a gut microbial metabolite in mice. Accordingly, a pilot human study was designed and completed to evaluate the safety of AB-2004 in an open-label, single-cohort, multiple-ascending-dose clinical trial that enrolled 30 adolescents with ASD and GI symptoms in New Zealand and Australia. AB-2004 was shown to have good safety and tolerability across all dose levels, and no drug-related serious adverse events were identified. Significant reductions in specific urinary and plasma levels of gut bacterial metabolites were observed between baseline and end of AB-2004 treatment, demonstrating likely target engagement. Furthermore, we observed improvements in multiple exploratory behavioral endpoints, most significantly in post hoc analysis of anxiety and irritability, as well as GI health, after 8 weeks of treatment. These results from an open-label study (trial registration no. ACTRN12618001956291) suggest that targeting gut-derived metabolites with an oral adsorbent is a safe and well-tolerated approach to improving symptoms associated with ASD, thereby emboldening larger placebo-controlled trials.
引用
- Stewart Campbell A, Needham BD, Meyer CR, et al. Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial. Nat Med. 2022. PMID: 35165451. doi:10.1038/s41591-022-01683-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。